DK0957941T3 - Anvendelse af et malanom differentieret associeret gen (mda-7) til at reversere en cancerøs fænotype - Google Patents

Anvendelse af et malanom differentieret associeret gen (mda-7) til at reversere en cancerøs fænotype

Info

Publication number
DK0957941T3
DK0957941T3 DK97940569.3T DK97940569T DK0957941T3 DK 0957941 T3 DK0957941 T3 DK 0957941T3 DK 97940569 T DK97940569 T DK 97940569T DK 0957941 T3 DK0957941 T3 DK 0957941T3
Authority
DK
Denmark
Prior art keywords
mda
reverse
cancerous phenotype
gene
cell
Prior art date
Application number
DK97940569.3T
Other languages
English (en)
Inventor
Paul B Fisher
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of DK0957941T3 publication Critical patent/DK0957941T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
DK97940569.3T 1996-08-16 1997-08-15 Anvendelse af et malanom differentieret associeret gen (mda-7) til at reversere en cancerøs fænotype DK0957941T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/696,573 US5710137A (en) 1996-08-16 1996-08-16 Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
PCT/US1997/014548 WO1998006441A1 (en) 1996-08-16 1997-08-15 USE OF A MELANOMA DIFFERENTIATION ASSOCIATED GENE (mda-7) FOR REVERSING A CANCEROUS PHENOTYPE

Publications (1)

Publication Number Publication Date
DK0957941T3 true DK0957941T3 (da) 2011-06-27

Family

ID=24797643

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97940569.3T DK0957941T3 (da) 1996-08-16 1997-08-15 Anvendelse af et malanom differentieret associeret gen (mda-7) til at reversere en cancerøs fænotype

Country Status (15)

Country Link
US (6) US5710137A (da)
EP (2) EP0957941B1 (da)
JP (2) JP4890666B2 (da)
KR (2) KR100574049B1 (da)
CN (2) CN1166409C (da)
AT (1) ATE505206T1 (da)
AU (1) AU727735B2 (da)
BR (1) BRPI9711137B8 (da)
CA (1) CA2263750C (da)
DE (1) DE69740175D1 (da)
DK (1) DK0957941T3 (da)
ES (1) ES2364513T3 (da)
NZ (1) NZ334034A (da)
SI (1) SI0957941T1 (da)
WO (1) WO1998006441A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE397066T1 (de) 1993-10-27 2008-06-15 Univ Columbia Methode zur bildung einer subtrahierten cdna bank und ihre verwendung
US6825320B1 (en) 1995-03-29 2004-11-30 Millenium Pharmaceuticals, Inc. FOHY03 polypeptides
US6251597B1 (en) 1996-03-29 2001-06-26 Millennium Pharmaceuticals, Inc. Methods for detecting fohy030
US6794185B1 (en) 1995-03-29 2004-09-21 Millennium Pharmaceuticals, Inc. fohy030 nucleic acid molecules
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US6312909B1 (en) 1996-03-29 2001-11-06 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis prevention and treatment of tumor progression
US5710137A (en) * 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
AU2469799A (en) * 1998-01-26 1999-08-09 Genquest Inc. Differentiation-associated sequences and methods of use therefor
US6413717B1 (en) 1998-03-18 2002-07-02 Corixa Corporation Methods for indentifying anti-cancer agents
WO1999060124A2 (en) * 1998-05-15 1999-11-25 Fei Huang Differentiation-associated sequences and methods of use therefor
JP2002535997A (ja) * 1999-02-02 2002-10-29 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 細胞の老化および細胞の最終分化の際に向上した発現を示す遺伝子、およびその使用
US6841362B1 (en) * 2000-02-29 2005-01-11 The Trustees Of Columbia University In The City Of New York Melanoma differentiation associated gene-7 promoter and uses thereof
EP1329106B1 (en) * 2000-10-15 2011-01-12 The DirecTV Group, Inc. Method and system for pause ads
CA2429769C (en) * 2000-12-07 2016-04-26 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
GB0109515D0 (en) * 2001-04-17 2001-06-06 Neg Micon As A method for transporting a set of large longitudinal items, a package system to be used by the method and use of such a package system
EP1281767A3 (en) * 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
US20030082140A1 (en) * 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
EP1490101A4 (en) * 2002-03-05 2006-09-20 Univ Texas PROCESS FOR IMPROVING IMMUNE INDUCTION WITH MDA-7
AU2003274963A1 (en) * 2002-12-23 2004-07-29 The Trustees Of Columbia University In The City Of New York Mda-7 and free radicals in the treatment of cancer
BRPI0408063A (pt) * 2003-03-03 2006-02-14 Univ Texas métodos e composições envolvendo mda-7
US20040229335A1 (en) * 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
WO2005047458A2 (en) 2003-06-18 2005-05-26 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
US8034790B2 (en) * 2003-12-01 2011-10-11 Introgen Therapeutics Use of MDA-7 to inhibit pathogenic infectious organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US20080026410A1 (en) * 2004-12-02 2008-01-31 Antonia Vlahou Biomarkers for Bladder Cancer
CA2597329C (en) * 2005-02-08 2016-10-11 Board Of Regents, The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2008156655A2 (en) * 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
KR200449370Y1 (ko) 2010-04-26 2010-07-06 범진아이엔디(주) 두께가 두꺼운 제품을 수축 및 기포없이 사출하는 금형
US10227289B2 (en) 2010-05-07 2019-03-12 Medicus Biosciences, Llc Methods for treating diseases of the lung
CN101935347B (zh) * 2010-07-27 2014-11-05 郑骏年 mda-7/IL-24去泛素化突变体
US11083821B2 (en) 2011-08-10 2021-08-10 C.P. Medical Corporation Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
US10111985B2 (en) 2011-08-10 2018-10-30 Medicus Biosciences, Llc Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
US10117885B2 (en) 2011-08-11 2018-11-06 Allergy Research Group, Llc Chewable lipid supplements for treating pain and fibromyalgia
JP6206987B2 (ja) 2012-05-11 2017-10-04 メディカス バイオサイエンシーズ，エルエルシー 網膜剥離の処置のための生体適合性ヒドロゲル製剤
CA2903823C (en) 2013-03-14 2021-08-31 Medicus Biosciences Llc Solid polyglycol-based biocompatible pre-formulation
AU2016349632A1 (en) * 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5643761A (en) * 1993-10-27 1997-07-01 The Trustees Of Columbia University In The City Of New York Method for generating a subtracted cDNA library and uses of the generated library
ATE397066T1 (de) 1993-10-27 2008-06-15 Univ Columbia Methode zur bildung einer subtrahierten cdna bank und ihre verwendung
US5710137A (en) 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
US6190909B1 (en) 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
US6440741B2 (en) 1999-03-15 2002-08-27 The Trustees Of Columbia University In The City Of New York Expression vector for consistent cellular expression of the tet on repressor in multiple cell types
DE60038508T2 (de) 1999-07-15 2009-04-30 Introgen Therapeutics Inc., Austin Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes

Also Published As

Publication number Publication date
JP2000516618A (ja) 2000-12-12
US6355622B1 (en) 2002-03-12
US7579330B2 (en) 2009-08-25
NZ334034A (en) 2000-10-27
EP0957941B1 (en) 2011-04-13
US20020091098A1 (en) 2002-07-11
KR100528047B1 (ko) 2005-11-15
CA2263750C (en) 2009-01-13
CA2263750A1 (en) 1998-02-19
JP4890666B2 (ja) 2012-03-07
AU727735B2 (en) 2000-12-21
CN1238697A (zh) 1999-12-15
KR100574049B1 (ko) 2006-04-27
BR9711137A (pt) 1999-08-17
BRPI9711137B1 (pt) 2016-01-26
EP0957941A1 (en) 1999-11-24
ES2364513T3 (es) 2011-09-05
CN1166409C (zh) 2004-09-15
ATE505206T1 (de) 2011-04-15
AU4231997A (en) 1998-03-06
WO1998006441A1 (en) 1998-02-19
US5710137A (en) 1998-01-20
EP0957941A4 (en) 2001-09-05
KR20000030021A (ko) 2000-05-25
JP2012051909A (ja) 2012-03-15
BRPI9711137B8 (pt) 2021-05-25
US20080057035A1 (en) 2008-03-06
US20100189680A1 (en) 2010-07-29
KR20050054946A (ko) 2005-06-10
CN100363057C (zh) 2008-01-23
US20050191277A1 (en) 2005-09-01
DE69740175D1 (de) 2011-05-26
EP2251040A1 (en) 2010-11-17
SI0957941T1 (sl) 2011-09-30
US7291605B2 (en) 2007-11-06
CN1575819A (zh) 2005-02-09
US6855686B2 (en) 2005-02-15

Similar Documents

Publication Publication Date Title
SI0957941T1 (sl) Uporaba z diferenciacijo melanoma povezanega gena (mda-7) za reverzijo rakavega fenotipa
IL128205A0 (en) Potassium channel inhibitors and pharmaceutical compositions containing the same
HU9303458D0 (en) Process for producing sulfonamides and pharmaceutical preparations containing them
DE3584281D1 (de) Tripeptidyl-argininaldehyde, verfahren zu ihrer herstellung und diese enthaltende arzneimittel sowie n-(monoalkyl)- und n,n-di-(alkyl)-xxx-l-prolin-dipeptide.
SE9702001D0 (sv) Novel compounds
DZ2420A1 (fr) Formulations nouvelles comprenant l'amoxycilline et du clavulanate et procédé pour leur préparation.
IL115790A0 (en) Pharmaceutical compositions containing boronic ester and acid compounds and methods for the preparation thereof
FI941262A0 (fi) 3-aroyylibentso(b)tiofeenien sulfonaatti- ja karbamaattijohdannaisia
MA23395A1 (fr) Procede de preparation de nouvelles formulations
PL343018A1 (en) Glucocorticoid-selective anti-inflammatory agents
EP0567088A3 (en) Process for the preparation of an amylase inhibitor.
EP0471756A4 (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof
FI920760A0 (fi) In vitro packningsystem foer kloning av dna-fragment med 95 kb.
IT1206730B (it) Amidi ed esteri di diidropiridinildicarbossilato farmaceuticamente utili.
PL340165A1 (en) Novel substituted dimeric compounds, method of obtaining them and pharmacological preparations containing such compounds
FR2702660B1 (fr) Compositions thérapeutiques stabilisées et leur procédé de préparation.
FI854910A0 (fi) Anordning foer distortionsfri utstrykning av display under en enskild bild.
NZ223293A (en) Beta-alkyl melatonins and pharmaceutical compositions
FR2712492B1 (fr) Compositions cosmétiques à base d'eaux thermales et leur procédé de préparation.
FR2674253B1 (fr) Composition lyophilisee pour la multiplication de sequences d'acides nucleiques.
TW218011B (da)
EP0723454A4 (en) Novel tripeptides useful in immune and cns therapy
FR2708928B1 (fr) Procédé de préparation de 2-halogéno-éthyl-malonates de dialkyle.
FR2711375B1 (fr) Procédé de détermination différentielle des activités des isoenzymes de l'alpha-amylase.
ATE46692T1 (de) (6,11-dihydro-11-oxodibenz(b,e>oxepinyl)pentaans|uren und derivate, verfahren und zwischenprodukte zu deren herstellung und deren verwendung als arzneimittel.